MedTrace Logo

Observational Study of NovoMix® 50 for Treatment of Type 2 Diabetics for 12 Months

NCT00755833 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 270

Last updated 2016-10-31

No results posted yet for this study

Summary

This study is conducted in Europe. The aim of this observational study is to evaluate the blood glucose control when using NovoMix® 50 up to 12 months after initiation subjects with type 2 diabetes currently on a therapy with human biphasic insulin. An additional objective is also to observe the different regimes of starting and maintaining the treatment with NovoMix® 50 during one year.

Conditions

Interventions

DRUG

biphasic insulin aspart 50

Efficacy and safety data collection in connection with the use of the drug NovoMix® 50 in daily clinical practice.

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2010-04-30
Completion
2010-04-30

Countries

  • Slovenia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00755833 on ClinicalTrials.gov